Market revenue in 2024 | USD 2,688.7 million |
Market revenue in 2030 | USD 3,823.2 million |
Growth rate | 6% (CAGR from 2025 to 2030) |
Largest segment | Evaporative dry eye syndrome |
Fastest growing segment | Evaporative Dry Eye Syndrome |
Historical data covered | 2018 - 2023 |
Base year for estimation | 2024 |
Forecast period covered | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Evaporative Dry Eye Syndrome, Aqueous Deficient Dry Eye Syndrome |
Key market players worldwide | Novartis AG ADR, AbbVie Inc, Sun Pharmaceutical Industries, Santen Pharmaceutical Co Ltd, Johnson & Johnson, Otsuka Pharmaceutical, OASIS Medical, Bausch & Lomb Corp, AFT Pharmaceuticals, Oyster Point Pharmaceuticals |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to dry eye syndrome treatment market will help companies and investors design strategic landscapes.
Evaporative dry eye syndrome was the largest segment with a revenue share of 82.5% in 2024. Horizon Databook has segmented the North America dry eye syndrome treatment market based on evaporative dry eye syndrome, aqueous deficient dry eye syndrome covering the revenue growth of each sub-segment from 2018 to 2030.
North America held the largest share of 42.01% of dry eye syndrome treatment market in 2022 owing to factors such as the rising prevalence of eye diseases and favorable government initiatives in the region. North America is a developed region with high healthcare expenditure. The local presence of regulatory entities in North American countries is expected to boost the development of dry eye treatment drugs in the near future.
This is mainly because these entities play a pivotal role in creating awareness among people about the potential of dry eye treatment therapies in disease management. Moreover, the high prevalence and increasing eye treatment procedures aid expansion in North America. High healthcare costs are among the primary factors driving market growth and boosting the demand for fast-acting and high-efficacy drugs.
A growing emphasis on personalized medicine, increasing collaborations & externalizations with academic research institutes, and rapid adoption of healthcare IT are some of the other factors anticipated to further propel the market growth in the region. Furthermore, increasing awareness about high-potency drugs, rising demand for dry eye treatment therapeutics, and a growing number of biotechnology companies are contributing to the region’s leading market share.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America dry eye syndrome treatment market , including forecasts for subscribers. This continent databook contains high-level insights into North America dry eye syndrome treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account